Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience

Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience

Nintedanib is a tyrosine kinase inhibitor which has shown to reduce the progression of idiopathic pulmonary fibrosis (IPF). [...]a follow-up PFT was available in only 12/20 patients. [...]significant numbers (6/25) of patients prescribed nintedanib could not commence or continue it due to high costs...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lung India 2019-09, Vol.36 (5), p.465-466, Article 465
Hauptverfasser: Mullerpattan, Jai, Porwal, Sana, Sarkar, Trina, Wagh, Haresh, Udwadia, Zarir
Format: Artikel
Sprache:eng
Schlagworte:
Drug dosages
Patients
Pulmonary fibrosis
Research Letters
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Nintedanib is a tyrosine kinase inhibitor which has shown to reduce the progression of idiopathic pulmonary fibrosis (IPF). [...]a follow-up PFT was available in only 12/20 patients. [...]significant numbers (6/25) of patients prescribed nintedanib could not commence or continue it due to high costs.
ISSN:0970-2113
0974-598X
DOI:10.4103/lungindia.lungindia_195_19